Phase 2
Completed N=29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
sarcoma · Sarcoma Metastatic
Source: ClinicalTrials.gov NCT04076579 ↗
Enrolled (actual)
29
Serious AEs
20.7%
Results posted
Jul 2024
Primary outcomePrimary: Overall Response Rate — 0; 2 Participants
Summary
This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing cells, stopping them from dividing or stopping them from spreading. Olaparib may stop the growth of tumor cells by blocking pathways responsible for repairing damaged cells. Giving trabectedin and olaparib may shrink or stop the tumor from growing.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Response Rate |
0; 2 | — |
| SECONDARY Progression Free Survival |
8.9; 20.2 | — |
| SECONDARY Overall Survival |
0.52; 0.48; 0; 0.12 | — |
| SECONDARY Incidence of Adverse Events |
0; 1; 1; 3; 5; 1 | — |
Eligibility Criteria
Key Inclusion Criteria
- Age ≥ 16 years
- Advanced unresectable or metastatic sarcoma
- Cohort 1: Leiomyosarcoma (LMS)/Liposarcoma (LPS)
- Cohort 2: Other sarcoma histologies (excluding gastrointestinal stromal tumors)
- Received at least 1 prior standard chemotherapy. For cohort 1 patients, this must have included a prior anthracycline.
- Measurable disease by RECIST 1.1
- Adequate hematologic, renal, hepatic function
- Adequate creatine phosphokinase
- ECOG performance status ≤ 1
- Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN)
- Women of childbearing potential and men must agree to use adequate contraception from signing informed consent to at least 6 months (females) and 5 months (men) after study drug treatment
Key Exclusion Criteria
- Prior therapy with PARP inhibitor, including olaparib
- Prior therapy with trabectedin
- Additional active malignancy or treatment for alternative cancer (excluding non-melanoma skin cancer) requiring treatment within the past two years
- Pregnant or breastfeeding women
- Known hypersensitivity to trabectedin or olaparib
- Other exclusions per protocol
Data sourced from ClinicalTrials.gov (NCT04076579). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.